Top

Osteoporosis International

Published in:

02-07-2022 | Osteoporosis | Original Article

Real-world evaluation of osteoporotic fractures using the Japan Medical Data Vision database

Authors: Saeko Fujiwara, Amy Buchanan-Hughes, Alvin Ng, Jennifer Page, Kenji Adachi, Hong Li

Published in: Osteoporosis International | Issue 10/2022

Abstract

Summary

In Japanese patients who experienced an osteoporotic fracture, 10.8% and 18.6% had a subsequent fracture within 1 and 2 years of follow-up, respectively. Although the burden of hip and vertebral fractures has been reported widely, we found that patients with non-hip non-vertebral (NHNV) fractures had a 26% higher risk of subsequent fracture than patients with hip fractures; therefore, NHNV fractures should also be considered an important risk factor for subsequent fracture.

Introduction

To investigate imminent risk and odds of subsequent osteoporotic fractures and associated risk factors in patients who experienced an initial osteoporotic fracture.

Methods

Patients aged ≥ 50 years with ≥ 1 osteoporotic fracture were analyzed from Japan’s Medical Data Vision (MDV) database of claims from acute-care hospitals (January 2012–January 2017). Multivariable models were constructed to explore the impact of key comorbidities and medications on the subsequent fracture risk: Cox proportional hazards model for time to subsequent fracture and logistic regression models for odds of subsequent fracture within 1 and 2 years from index fracture.

Results

In total, 32,926 patients were eligible with a median follow-up duration of 12.3 months. The percentage of patients experiencing subsequent fractures was 14.1% across the study duration, and 10.8% and 18.6% in patients with 1 and 2 years of follow-up, respectively. In the Cox proportional hazards model, patients with vertebral or NHNV index fractures had a higher subsequent fracture risk than patients with a hip index fracture (adjusted hazard ratio [aHR] 1.11 and 1.26, respectively); subsequent fracture risk was lower in males than females (aHR 0.89). Patients with baseline claims for tranquilizers and glucocorticoids had a higher subsequent fracture risk than those without (aHR 1.14 and 1.08, respectively). Additionally, baseline claims for anti-Parkinson’s medications, alcoholism, and stage 4/5 chronic kidney disease were significantly associated with higher odds of subsequent fracture in the logistic regression models.

Conclusion

Several clinical and demographic factors were associated with a higher risk and odds of subsequent fracture. This may help to identify patients who should be prioritized for osteoporosis treatment.

Available only for authorised users

Orimo H, Nakamura T, Hosoi T et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis–executive summary. Arch Osteoporos 7:3–20. https://doi.org/10.1007/s11657-012-0109-9CrossRefPubMedPubMedCentral

Committee of Japanese Guidelines for the Prevention and Treatment of Osteoporosis (2015) Japanese guidelines for the prevention and treatment of osteoporosis, 2015th edn. Life Science Publishing, Tokyo, Japan, pp 2–3 (in Japanese)

International Osteoporosis Foundation (n.d.) Fragility fractures epidemiology. https://www.osteoporosis.foundation/health-professionals/fragility-fractures/epidemiology. Accessed 2 June 2021

Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382. https://doi.org/10.1016/j.bone.2004.03.024CrossRefPubMed

Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739. https://doi.org/10.1359/jbmr.2000.15.4.721CrossRefPubMed

van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68:99–102. https://doi.org/10.1136/ard.2008.092775CrossRefPubMed

Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775–780. https://doi.org/10.1007/s00198-016-3868-0CrossRefPubMed

Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E (2012) Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27:2039–2046. https://doi.org/10.1002/jbmr.1698CrossRefPubMed

Åkesson K, Marsh D, Mitchell PJ, McLellan A, Stenmark J, Pierroz D, Kyer C, Cooper C (2013) Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24:2135–2152. https://doi.org/10.1007/s00198-013-2348-zCrossRefPubMedPubMedCentral

10.

Li N, Hiligsmann M, Boonen A, van Oostwaard M, de Bot R, Wyers C, Bours S, van den Bergh J (2021) The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis. Osteoporos Int 32:1517–1530CrossRef

11.

University of Sheffield Centre for Metabolic Bone Diseases (2008) FRAX® Fracture risk assessment tool. https://www.sheffield.ac.uk/FRAX/. Accessed 11 Nov 2019

12.

Sobue T, Fukuda H, Matsumoto T, Lee B, Ito S, Iwata S (2021) The background occurrence of selected clinical conditions prior to the start of an extensive national vaccination program in Japan. PLoS ONE 16:e0256379. https://doi.org/10.1371/journal.pone.0256379CrossRefPubMedPubMedCentral

13.

Medical Data Vision Co. (2017) Press release - overview of database. https://www.mdv.co.jp/press/2017/detail_728.html. Accessed 25 Feb 2021

14.

Taguchi Y, Inoue Y, Kido T, Arai N (2018) Treatment costs and cost drivers among osteoporotic fracture patients in Japan: a retrospective database analysis. Arch Osteoporos 13:45. https://doi.org/10.1007/s11657-018-0456-2CrossRefPubMedPubMedCentral

15.

Imai K, Petigara T, Kohn MA, Nakashima K, Aoshima M, Shito A, Kanazu S (2018) Risk of pneumococcal diseases in adults with underlying medical conditions: a retrospective, cohort study using two Japanese healthcare databases. BMJ Open 8:e018553. https://doi.org/10.1136/bmjopen-2017-018553CrossRefPubMedPubMedCentral

16.

Nakamura M (2016) Utilization of MDV data and data quality control. Japan Pharmacoepidemiol 21:23–25. https://doi.org/10.3820/jjpe.21.23CrossRef

17.

Hagino H, Sawaguchi T, Endo N, Ito Y, Nakano T, Watanabe Y (2011) The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 90:14–21. https://doi.org/10.1007/s00223-011-9545-6CrossRefPubMed

18.

Barron RL, Oster G, Grauer A, Crittenden DB, Weycker D (2020) Determinants of imminent fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 31:2103–2111. https://doi.org/10.1007/s00198-020-05294-3CrossRefPubMedPubMedCentral

19.

Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A, Curtis JR (2019) Risk of subsequent fracture after prior fracture among older women. Osteoporos Int 30:79–92. https://doi.org/10.1007/s00198-018-4732-1CrossRefPubMed

20.

Kanis JA, Johansson H, Odén A, Harvey NC, Gudnason V, Sanders KM, Sigurdsson G, Siggeirsdottir K, Fitzpatrick LA, Borgström F (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747–1757. https://doi.org/10.1007/s00198-018-4502-0CrossRefPubMedPubMedCentral

21.

Park JA, Nam JH, Hong SH, Shim YB, Jeong J, Shin JY (2020) Economic burden of subsequent fracture in osteoporosis patients in South Korea. J Med Econ 23:1598–1605. https://doi.org/10.1080/13696998.2020.1831517CrossRefPubMed

22.

Khalid S, Pineda-Moncusí M, El-Hussein L, Delmestri A, Ernst M, Smith C, Libanati C, Toth E, Javaid MK, Cooper C (2021) Predicting imminent fractures in patients with a recent fracture or starting oral bisphosphonate therapy: development and international validation of prognostic models. J Bone Miner Res 36:2162–2176CrossRef

23.

Iconaru L, Charles A, Baleanu F, Surquin M, Benoit F, Mugisha A, Moreau M, Paesmans M, Karmali R, Rubinstein M (2022) Prediction of an imminent fracture after an index fracture–models derived from the Frisbee cohort. J Bone Miner Res 37:59–67CrossRef

24.

Rubin KH, Möller S, Holmberg T, Bliddal M, Søndergaard J, Abrahamsen B (2018) A new fracture risk assessment tool (FREM) based on public health registries. J Bone Miner Res 33:1967–1979CrossRef

25.

Möller S, Skjødt MK, Yan L, Abrahamsen B, Lix LM, McCloskey EV, Johansson H, Harvey NC, Kanis JA, Rubin KH (2022) Prediction of imminent fracture risk in Canadian women and men aged 45 years or older: external validation of the Fracture Risk Evaluation Model (FREM). Osteoporos Int 33:57–66CrossRef

26.

Cawthon PM (2011) Gender differences in osteoporosis and fractures. Clin Orthop Relat Res 469:1900–1905. https://doi.org/10.1007/s11999-011-1780-7CrossRefPubMedPubMedCentral

27.

Toth E, Banefelt J, Åkesson K, Spångeus A, Ortsäter G, Libanati C (2020) History of previous fracture and imminent fracture risk in Swedish women aged 55 to 90 years presenting with a fragility fracture. J Bone Miner Res 35:861–868. https://doi.org/10.1002/jbmr.3953CrossRefPubMed

28.

Ji MX, Yu Q (2015) Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med 1:9–13. https://doi.org/10.1016/j.cdtm.2015.02.006CrossRefPubMedPubMedCentral

29.

Söreskog E, Ström O, Spångéus A, Åkesson KE, Borgström F, Banefelt J, Toth E, Libanati C, Charokopou M (2020) Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone 134:115286. https://doi.org/10.1016/j.bone.2020.115286CrossRefPubMed

30.

Briot K, Roux C (2015) Glucocorticoid-induced osteoporosis. RMD Open 1:e000014. https://doi.org/10.1136/rmdopen-2014-000014CrossRefPubMedPubMedCentral

31.

Pereira RM, Carvalho JF, Canalis E (2010) Glucocorticoid-induced osteoporosis in rheumatic diseases. Clin (Sao Paulo) 65:1197–1205. https://doi.org/10.1590/s1807-59322010001100024CrossRef

32.

de Jong MR, Van der Elst M, Hartholt KA (2013) Drug-related falls in older patients: implicated drugs, consequences, and possible prevention strategies. Ther Adv Drug Saf 4:147–154. https://doi.org/10.1177/2042098613486829CrossRefPubMedPubMedCentral

33.

American Geriatrics Society (2019) Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 67:674–694. https://doi.org/10.1111/jgs.15767CrossRef

34.

Allen NE, Schwarzel AK, Canning CG (2013) Recurrent falls in Parkinson’s disease: a systematic review. Parkinsons Dis 2013:906274. https://doi.org/10.1155/2013/906274CrossRefPubMedPubMedCentral

35.

Kalilani L, Asgharnejad M, Palokangas T, Durgin T (2016) Comparing the incidence of falls/fractures in Parkinson’s disease patients in the US population. PLoS ONE 11:e0161689. https://doi.org/10.1371/journal.pone.0161689CrossRefPubMedPubMedCentral

36.

Zhao DM, Cheng P, Zhu B (2016) Epilepsy and fracture risk: a meta-analysis. Int J Clin Exp Med 9:564–569

37.

Camicioli R, Licis L (2004) Motor impairment predicts falls in specialized Alzheimer care units. Alzheimer Dis Assoc Disord 18:214–218PubMed

38.

Qunibi WY (2020) Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD). UpToDate. https://www.uptodate.com/contents/overview-of-chronic-kidney-disease-mineral-and-bone-disorder-ckd-mbd. Accessed 2 Mar 2021

39.

Dawson-Hughes B (2021) Vitamin D deficiency in adults: definition, clinical manifestations, and treatment. UpToDate. https://www.uptodate.com/contents/vitamin-d-deficiency-in-adults-definition-clinical-manifestations-and-treatment. Accessed 22 Mar 2021

40.

Avenell A, Mak JC, O'Connell D (2014) Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev. 2014:CD000227. https://doi.org/10.1002/14651858.CD000227.pub4

41.

Shikari M, Kushida K, Yamazaki K, Nagai T, Inoue T, Orimo H (1996) Effects of 2 years’ treatment of osteoporosis with 1 alpha-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocr J 43:211–220. https://doi.org/10.1507/endocrj.43.211CrossRefPubMed

42.

Richy F, Deroisy R, Lecart MP, Hanssens L, Mawet A, Reginster JY (2005) D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clin Exp Res 17:133–142. https://doi.org/10.1007/bf03324586CrossRefPubMed

43.

Xu Z, Fan C, Zhao X, Tao H (2016) Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials. Drug Des Devel Ther 10:509–517. https://doi.org/10.2147/dddt.S84264CrossRefPubMedPubMedCentral

44.

Gaddini GW, Turner RT, Grant KA, Iwaniec UT (2016) Alcohol: a simple nutrient with complex actions on bone in the adult skeleton. Alcohol Clin Exp Res 40:657–671. https://doi.org/10.1111/acer.13000CrossRefPubMedPubMedCentral

45.

Nishimura R, Kato H, Kisanuki K, Oh A, Hiroi S, Onishi Y, Guelfucci F, Shimasaki Y (2019) Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. BMJ Open 9:e025806. https://doi.org/10.1136/bmjopen-2018-025806CrossRefPubMedPubMedCentral

46.

Kawachi I, Okamoto S, Sakamoto M, Ohta H, Nakamura Y, Iwasaki K, Yoshida M, Hiroi S, Ogino M (2019) Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database. BMC Neurol 19:1–10. https://doi.org/10.1186/s12883-019-1534-9CrossRef

47.

ClinRisk Ltd (2016) QFracture Risk Calculator. https://qfracture.org/. Accessed 22 Mar 2021

48.

Heinze G, Wallisch C, Dunkler D (2018) Variable selection–a review and recommendations for the practicing statistician. Biom J 60:431–449. https://doi.org/10.1002/bimj.201700067CrossRefPubMedPubMedCentral

Title: Real-world evaluation of osteoporotic fractures using the Japan Medical Data Vision database
Authors: Saeko Fujiwara
Amy Buchanan-Hughes
Alvin Ng
Jennifer Page
Kenji Adachi
Hong Li
Publication date: 02-07-2022
Publisher: Springer London
Keywords: Osteoporosis
Osteoporosis
Tranquilizer
Published in: Osteoporosis International / Issue 10/2022
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-022-06472-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Real-world evaluation of osteoporotic fractures using the Japan Medical Data Vision database

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2022

Correction to: The clinician’s guide to prevention and treatment of osteoporosis

Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study

Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan

Comment on “Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer”: Waxing-Waning Serum Calcium following Denosumab use in a patient with Polyostotic Paget’s Disease of Bone

Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study

Surgical treatment for fragility hip fractures during the COVID-19 pandemic resulted in lower short-term postoperative functional outcome and a higher complication rate compared to the pre-pandemic period